Human Biome S.A. Secures $4M in Series A First Tranche to Advance Biosynthetic Microbiome Platform
We are thrilled to announce that Human Biome S.A. has officially closed the first tranche of our Series A funding round, raising $4 million.
This capital injection will accelerate the development of our biosynthetic microbiome platform—a technology with the potential to fundamentally transform how we treat chronic lifestyle diseases and age-related conditions.
A Heartfelt Thank You to Our Partners and Team
Achieving this milestone would not be possible without the trust and shared vision of our investors. We extend our deepest gratitude to IGS ASI and the NCBR Investment Fund (NIF ASI) for backing our mission.
What’s Next? Driving the Future of Medicine
We are channeling this funding directly into the development of New-Generation Biotherapeutics (NGB). Moving forward, our pipeline will heavily focus on two critical healthcare frontiers:
-
Combating Antimicrobial Resistance: Developing novel solutions to tackle the global threat of drug-resistant bacteria.
-
Healthy Ageing & Longevity: Researching therapies aimed at extending healthspan and promoting vital aging.
-
Key Milestones Ahead: We are laser-focused on advancing our first preclinical drug candidate (HBI-001) and conducting Proof of Concept studies aimed at reversing biological age and counteracting unhealthy aging processes.
We are proudly building a deep-tech powerhouse that seamlessly bridges the gap between advanced science, engineering, and a tangible, life-changing impact on human health.
Warsaw, January 2026
